192 related articles for article (PubMed ID: 34281237)
1. Mechanism of the Conformational Change of the Protein Methyltransferase SMYD3: A Molecular Dynamics Simulation Study.
Sun J; Li Z; Yang N
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281237
[TBL] [Abstract][Full Text] [Related]
2. Smyd3 open & closed lock mechanism for substrate recruitment: The hinge motion of C-terminal domain inferred from μ-second molecular dynamics simulations.
Chandramouli B; Silvestri V; Scarno M; Ottini L; Chillemi G
Biochim Biophys Acta; 2016 Jul; 1860(7):1466-74. PubMed ID: 27085704
[TBL] [Abstract][Full Text] [Related]
3. Exploration of the Substrate Preference of Lysine Methyltransferase SMYD3 by Molecular Dynamics Simulations.
Sun J; Shi F; Yang N
ACS Omega; 2019 Nov; 4(22):19573-19581. PubMed ID: 31788587
[TBL] [Abstract][Full Text] [Related]
4. Structural Basis for Substrate Preference of SMYD3, a SET Domain-containing Protein Lysine Methyltransferase.
Fu W; Liu N; Qiao Q; Wang M; Min J; Zhu B; Xu RM; Yang N
J Biol Chem; 2016 Apr; 291(17):9173-80. PubMed ID: 26929412
[TBL] [Abstract][Full Text] [Related]
5. Conformational Dynamics of Lysine Methyltransferase Smyd2. Insights into the Different Substrate Crevice Characteristics of Smyd2 and Smyd3.
Chandramouli B; Chillemi G
J Chem Inf Model; 2016 Dec; 56(12):2467-2475. PubMed ID: 27959541
[TBL] [Abstract][Full Text] [Related]
6. New open conformation of SMYD3 implicates conformational selection and allostery.
Spellmon N; Sun X; Xue W; Holcomb J; Chakravarthy S; Shang W; Edwards B; Sirinupong N; Li C; Yang Z
AIMS Biophys; 2017; 4(1):1-18. PubMed ID: 28050603
[TBL] [Abstract][Full Text] [Related]
7. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.
Mazur PK; Reynoird N; Khatri P; Jansen PW; Wilkinson AW; Liu S; Barbash O; Van Aller GS; Huddleston M; Dhanak D; Tummino PJ; Kruger RG; Garcia BA; Butte AJ; Vermeulen M; Sage J; Gozani O
Nature; 2014 Jun; 510(7504):283-7. PubMed ID: 24847881
[TBL] [Abstract][Full Text] [Related]
8. Structural insights into the autoinhibition and posttranslational activation of histone methyltransferase SmyD3.
Sirinupong N; Brunzelle J; Doko E; Yang Z
J Mol Biol; 2011 Feb; 406(1):149-59. PubMed ID: 21167177
[TBL] [Abstract][Full Text] [Related]
9. Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets.
Van Aller GS; Graves AP; Elkins PA; Bonnette WG; McDevitt PJ; Zappacosta F; Annan RS; Dean TW; Su DS; Carpenter CL; Mohammad HP; Kruger RG
Structure; 2016 May; 24(5):774-781. PubMed ID: 27066749
[TBL] [Abstract][Full Text] [Related]
10. Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening.
Gradl S; Steuber H; Weiske J; Szewczyk MM; Schmees N; Siegel S; Stoeckigt D; Christ CD; Li F; Organ S; Abbey M; Kennedy S; Chau I; Trush V; Barsyte-Lovejoy D; Brown PJ; Vedadi M; Arrowsmith C; Husemann M; Badock V; Bauser M; Haegebarth A; Hartung IV; Stresemann C
SLAS Discov; 2021 Sep; 26(8):947-960. PubMed ID: 34154424
[TBL] [Abstract][Full Text] [Related]
11. Structural and biochemical studies of human lysine methyltransferase Smyd3 reveal the important functional roles of its post-SET and TPR domains and the regulation of its activity by DNA binding.
Xu S; Wu J; Sun B; Zhong C; Ding J
Nucleic Acids Res; 2011 May; 39(10):4438-49. PubMed ID: 21266482
[TBL] [Abstract][Full Text] [Related]
12. Unveiling the Biochemistry of the Epigenetic Regulator SMYD3.
Fabini E; Talibov VO; Mihalic F; Naldi M; Bartolini M; Bertucci C; Del Rio A; Danielson UH
Biochemistry; 2019 Sep; 58(35):3634-3645. PubMed ID: 31389685
[TBL] [Abstract][Full Text] [Related]
13. Crystal structures of histone and p53 methyltransferase SmyD2 reveal a conformational flexibility of the autoinhibitory C-terminal domain.
Jiang Y; Sirinupong N; Brunzelle J; Yang Z
PLoS One; 2011; 6(6):e21640. PubMed ID: 21738746
[TBL] [Abstract][Full Text] [Related]
14. Discovery of an Allosteric Ligand Binding Site in SMYD3 Lysine Methyltransferase.
Talibov VO; Fabini E; FitzGerald EA; Tedesco D; Cederfeldt D; Talu MJ; Rachman MM; Mihalic F; Manoni E; Naldi M; Sanese P; Forte G; Lepore Signorile M; Barril X; Simone C; Bartolini M; Dobritzsch D; Del Rio A; Danielson UH
Chembiochem; 2021 May; 22(9):1597-1608. PubMed ID: 33400854
[TBL] [Abstract][Full Text] [Related]
15. Structure of human lysine methyltransferase Smyd2 reveals insights into the substrate divergence in Smyd proteins.
Xu S; Zhong C; Zhang T; Ding J
J Mol Cell Biol; 2011 Oct; 3(5):293-300. PubMed ID: 21724641
[TBL] [Abstract][Full Text] [Related]
16. Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents.
Rajajeyabalachandran G; Kumar S; Murugesan T; Ekambaram S; Padmavathy R; Jegatheesan SK; Mullangi R; Rajagopal S
Expert Opin Ther Targets; 2017 Feb; 21(2):145-157. PubMed ID: 28019723
[TBL] [Abstract][Full Text] [Related]
17. Lysine methylation in cancer: SMYD3-MAP3K2 teaches us new lessons in the Ras-ERK pathway.
Colón-Bolea P; Crespo P
Bioessays; 2014 Dec; 36(12):1162-9. PubMed ID: 25382779
[TBL] [Abstract][Full Text] [Related]
18. Hit identification of SMYD3 enzyme inhibitors using structure-based pharmacophore modeling.
Alnabulsi SM; Al-Shar'i NA
Future Med Chem; 2019 May; 11(10):1107-1117. PubMed ID: 31280673
[No Abstract] [Full Text] [Related]
19. Structural and functional profiling of the human histone methyltransferase SMYD3.
Foreman KW; Brown M; Park F; Emtage S; Harriss J; Das C; Zhu L; Crew A; Arnold L; Shaaban S; Tucker P
PLoS One; 2011; 6(7):e22290. PubMed ID: 21779408
[TBL] [Abstract][Full Text] [Related]
20. Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization.
Yoshioka Y; Suzuki T; Matsuo Y; Tsurita G; Watanabe T; Dohmae N; Nakamura Y; Hamamoto R
Cancer Med; 2017 Jul; 6(7):1665-1672. PubMed ID: 28639750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
